Documentos de Mazorra Z. | REDI

Regresar

Mostrando 4 resultados de: 4

Filtros aplicados

Palabras Claves: "Itolizumab"

Subtipo de publicación

Publisher

Clinical and Translational Immunology(1)

Immunity and Ageing(1)

Immunotherapy(1)

Área temáticas

Enfermedades(4)

Farmacología y terapéutica(3)

Microorganismos, hongos y algas(2)

Área de conocimiento

Inmunología(4)

Año de Publicación

Origen

Palabras Claves

Cytokine release syndrome(2)

Monoclonal antibody(2)

Anti-idiotypic antibody response(1)

An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases

Abstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the di

Palabras claves:

CD6 molecule, coronavirus 2, covid-19, cytokine-release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-COV-2

Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients

Abstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around the

Palabras claves:

covid-19, Cytokine release syndrome, IL-6, Itolizumab

Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Filgueira L.M., Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab

Abstract: Rheumatoid arthritis is an autoimmune disease characterized by joint inflammation that affects appro

Palabras claves:

Anti-idiotypic antibody response, Itolizumab, Peripheral lymphocytic counts, Proinflammatory cytokines, Rheumatoid Arthritis

Aira L.E., Carmen Elena Viada, Chico A., Fuentes K.P., Gómez J.A., Gonzalez Z., Hernández P., Mazorra Z., Prada D.M.

Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab

Abstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on matur

Palabras claves:

CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2

Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.